GEN-MKT-18-7897-A
Feb 15, 2017 | Biopharma, Blogs | 0 comments
Did you know the X500B QTOF system makes point and click workflows for Biologics Characterization possible on your mass spectrometer? The newly-designed SCIEX OS software interface brings to life fluid navigation and ease of use so you can keep moving forward on your scientific discoveries. In fact, it’s so simple to learn and operate that you and your team can be up and running faster than you might expect.
Hard to believe? Check out our new video series and see how easy it can be to get started with SCIEX OS on the X500B QTOF system.
Move Your Biotherapeutic Along FasterWhat’s different with the X500B? The new SCIEX OS software was built from the ground up to facilitate the X500B’s usability for every scientist, not just mass spec experts. The software uses an intuitive, icon-oriented interface so you can logically set up and optimize new methods. Instead of spending time and money on advanced training, you simply get to work. What’s more, SCIEX OS software features simple point and click method-building tools to create and optimize high-performance methods.
Let Your Productivity Soar the X500B QTOF and SCIEX OS Software:
You’ll be surprised how simple it is to increase your productivity.
Watch the short SCIEX OS introduction video series to see how easy it is for you to get fast, high-quality results in the point and click world.
Finding the right information shouldn’t slow you down. Whether you’re troubleshooting your mass spec, learning something new, or optimizing performance, access to the right resources at the right moment makes all the difference.
As an analytical strategy, middle-down mass spectrometry (MS) workflows characterize biotherapeutic proteins by analyzing large, digested protein fragments or defined subunits, rather than fully intact proteins (top-down) or digested peptides (bottom-up). A middle-down strategy combines the strengths of top-down and bottom-up approaches by delivering high sequence coverage and structural specificity while maintaining relatively simple sample preparation. In practice, middle-down analysis enables accurate mass measurement, rapid sequence confirmation, and localization of key post-translational modifications (PTMs) on protein subunits that are directly relevant to product quality.
In biopharmaceutical development, sequence variants (SV) are considered an inherent risk of producing complex proteins in living systems. Sequence variants are unintended changes to the amino acid sequence of a biotherapeutic and can be caused by errors in transcription or translation in the host cell, or cell culture and process conditions. Detailed analysis of SVs is important in process and product development to ensure the drug’s safety and efficacy. Even low‑level sequence variants can have significant implications for product quality, safety, and efficacy, making their accurate detection and characterization a critical requirement across development, process optimization, and regulatory submission.
Posted by
You must be logged in to post a comment.
Share this post with your network